Skip to main content area Skip to main content area Skip to institutional navigation Skip to search Skip to section navigation

Osagie Imasogie GL'85

Adjunct Professor of Law

Osagie Imasogie

Senior Managing Partner, Phoenix IP Ventures

Osagie has over 28 years of experience in the fields of law, finance and business management, healthcare and the pharmaceutical industry.  Prior to co-founding Phoenix IP Ventures, an IP based Merchant Bank, Osagie conceptualized and established GlaxoSmithKline Ventures and was its founding Vice President. Osagie led GSK Ventures in concluding over thirty (30) worldwide transactions, within a 3 year period, in which he invested various GSK R&D non-progressed assets into various companies and/or as the basis of starting new companies.

Prior to this role within GSK, Osagie was a Vice President for Product Development Strategy at SmithKline Beecham. Prior to this role at SmithKline, Osagie was the Founding Senior Vice President for Business Development and General Counsel at Endo Pharmaceuticals Inc., a multi-Billion publicly traded specialist pharmaceutical company. Osagie previously served as a DuPont Merck Vice President for International Sales and Marketing and General Counsel to DuPont Merck’s International, Manufacturing and Generic Drug Divisions. Osagie has also been a Price Waterhouse Corporate Finance Partner and the Partner-in-Charge for PW Corporate Finance activities for West Africa as well as a practicing attorney with a leading US Law Firm in the fields of corporate, corporate finance, taxation and intellectual property law.  
Most recently, Osagie was a co-Founder and former President, CEO and Chairman of Ception Therapeutics. Inc., a biopharmaceutical company focused on the discovery and development of novel products to address unmet medical needs. Osagie was also the Founder of Trigenesis Therapeutics Inc., a biopharmaceutical company focused on developing pharmaceutical products for the dermatological market which he sold to a publicly traded pharmaceutical company. Osagie is Chairman of the Board of Directors of iCeutica Pharmaceuticals, Inc. as well as Iroko Pharmaceuticals LLC. In addition, he serves on the Board of StoneRidge Investment Partners, a Money Management Firm with over $300MM under management. Osagie is also the Chairman of the Advisory Board for Quoin Capital, a Philadelphia based, full service Investment Bank. 
In addition, Osagie is a member of the Board of Overseers of the University of Pennsylvania Law School. Osagie is also the 2008 recipient of the Penn Law School Alumni Award of Merit. For six years (2000-2005), Osagie was Chairman of the Board of Trustees of the International House of Philadelphia. Osagie is also a member of the Wilson Council of the Woodrow Wilson International Center for Scholars in Washington DC, in addition to a number of other non-for-profit organizations and institutions such as the Philadelphia Orchestra. Osagie also served as a Senior Consultant to the President’s Emergency Plan For Aids Relief (PEPFAR), a unique initiative by the United States Government to have a direct, positive impact in the fight against the global Aids epidemic by committing, at that time, over a five-year period, $15 Billion and a multifaceted approach to combating HIV/AIDS. 
Osagie holds post-graduate degrees from the London School of Economics and the University of Pennsylvania Law School, is a member of the New York State Bar. In addition, Osagie is the I Grant Irey Adjunct Professor at the University of Pennsylvania Law School where he teaches a seminar on “Intellectual Property and National Economic Value Creation”.

⇱ Return to Top